-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Artificial Intelligence in Lung Cancer: Opening New Avenues for Detection, Diagnosis, and Prognostication
By Mizuki Nishino, MD, MPH Posted: April 16, 2020 Dr. Mizuki Nishino Artificial intelligence (AI) approaches have emerged as promising tools to address important unmet needs across different specialties in medicine, including oncology, radiology, and pathology. Recent studies have described the utility of AI in lung cancer to improve detection, diagnosis, and prognostication. Many of…
-
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are now available in routine clinical practice for the treatment of patients with advanced or metastatic NSCLC and SCLC. Several biomarkers have been reported to predict…
-
#LCSM Chat Topic 6/4/2020: #ASCO20 Roundup for #LungCancer
Please join #LCSM Chat Thursday, June 4, 2020, at 8 pm Eastern time (5 pm Pacific) to discuss the ASCO 2020 Annual Virtual Meeting presentations related to lung cancer. Usually, the ASCO Annual Meeting is held in Chicago, Illinois at the end of May/beginning of June, and attracts over 40,000 attendees from around the world. Due to…
-
Lung Cancer Considered – Episode XXV – Mar 16, 2020 Dr. Marty Edelman Speaks With IASLC President Dr. Tetsuya Mitsudomi
Posted: April 16, 2020 In this latest episode of Lung Cancer Considered, the official podcast of the IASLC, Dr. Marty Edelman speaks with IASLC President Dr. Tetsuya Mitsudomi. Download the podcast. New episodes of Lung Cancer Considered are released on the first and third Monday of each month.
-
Gustave Roussy’s New Leadership
Posted: April 16, 2020 Professor Jean-Charles Soria has been appointed general director of Gustave Roussy for a term of 5 years. A medical oncologist and professor of medicine at Paris-Saclay University, Prof. Soria was the director of the Gustave-Roussy SIRIC Socrate (Integrated Cancer Research Site) between 2012 and 2017. Since September 2017, Prof. Soria was…
-
Fred Hutchinson’s New President, Director
Posted: April 16, 2020 Dr. Thomas J. Lynch Jr. has been named the new president and director of the Fred Hutchinson Cancer Research Center. Most recently Dr. Lynch was chief scientific officer at Bristol- Myers Squibb, where he oversaw research and development for oncology, cardiovascular disease, fibrosis, and immunoscience. Previously chairman and CEO of Massachusetts…
-
Grappling with Coronavirus (SARS-CoV-2)
By Corey J. Langer, MD, ILCN Editor Posted: April 16, 2020 Dr. Corey Langer Michele Carbone MD, Ph.D and colleagues have penned a far-ranging editorial, now published online in the Journal of Thoracic Oncology (JTO), on the “Facts, Myths, and Hypotheses” behind this pandemic and global public health crisis, which was first documented in Hubei…
-
Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other Agents Targeting EGFR Mutations
By Denis Moro-Sibilot, MD, MSc Posted: April 16, 2020 Dr. Denis Moro-Sibilot EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of the burning questions is whether to select the most recent third-generation agent or to combine a first- or second-generation TKI with chemotherapy or antiangiogenic agents and…
-
Member Story: Dr. Shengxiang Ren
Dr. Shengxiang Ren is an associate professor at Shanghai Pulmonary Hospital, Tongji University and Vice Director at Shanghai Pulmonary Hospital. He is a vice header of interventional section in the Shanghai Medical Association Respiratory Branch and Youth Committee Member in Shanghai Anti-Cancer Association. He is a member of the CTONG Trials Group and participant of…
-
Member Story: Dr. Amy Moore
Dr. Amy Moore—USA Dr. Amy Moore is the Director of Science and Research for the GO2 Foundation for Lung Cancer and based in the San Francisco Bay area, shares her thoughts on the current COVID-19 pandemic and what it means for the lung cancer community. I guess my perspective is a unique one because my doctorate…